Ebola virus vaccines: an overview of current approaches

References

• Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editor. Fields virology. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2006. p. 1409-48
   Google Scholar
• Outbreak news. Ebola haemorrhagic fever, Uganda – update. Releve epidemiologique hebdomadaire/ Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/ Health Section of the Secretariat of the League of Nations. 2012;87:493
   Google Scholar
• Outbreak news. Ebola haemorrhagic fever, Democratic Republic of the Congo. Releve epidemiologique hebdomadaire/ Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/ Health Section of the Secretariat of the League of Nations. 2012;87:338-9
   Google Scholar
• Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009;2:12-17
   PubMed Web of Science ®Google Scholar
• Ebihara H, Zivcec M, Gardner D, et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis 2013;207:306-18
   PubMed Web of Science ®Google Scholar
• Safronetz D, Geisbert TW, Feldmann H. Animal models for highly pathogenic emerging viruses. Curr Opin Virol 2013;3:205-9
   PubMedGoogle Scholar
• Lupton HW, Lambert RD, Bumgardner DL, et al. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet 1980;2:1294-5
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002;8:503-7
   PubMed Web of Science ®Google Scholar
• Hoenen T, Groseth A, Feldmann H. Current ebola vaccines. Expert Opin Biol Ther 2012;12:859-72
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Negley DL, et al. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005;23:3033-42
   PubMed Web of Science ®Google Scholar
• Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003;100:15889-94
   PubMed Web of Science ®Google Scholar
• Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005;175:1184-91
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007;196(Suppl 2):S430-7
   PubMed Web of Science ®Google Scholar
• Warfield KL, Aman MJ. Advances in virus-like particle vaccines for filoviruses. J Infect Dis 2011;204(Suppl 3):S1053-9
   PubMed Web of Science ®Google Scholar
• Warfield KL, Posten NA, Swenson DL, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 2007;196(Suppl 2):S421-9
   PubMed Web of Science ®Google Scholar
• Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines–immune responses. Vaccine 2012;30(Suppl 5):F83-7
   PubMed Web of Science ®Google Scholar
• Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000;19:142-53
   PubMed Web of Science ®Google Scholar
• Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001;286:384-90
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001;75:2660-4
   PubMed Web of Science ®Google Scholar
• Lee JS, Groebner JL, Hadjipanayis AG, et al. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006;24:6886-92
   PubMed Web of Science ®Google Scholar
• Herbert AS, Kuehne AI, Barth JF, et al. Venezuelan equine encephalitis replicon particle vaccine protects nonhuman primates from ebolavirus intramuscular and aerosol challenge. J Virol 2013; 87(9):4952-64
   Google Scholar
• Reynard O, Mokhonov V, Mokhonova E, et al. Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J Infect Dis 2011;204(Suppl 3):S1060-5
   PubMedGoogle Scholar
• Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008;7:175-91
   PubMed Web of Science ®Google Scholar
• Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998;246:134-44
   PubMed Web of Science ®Google Scholar
• Riemenschneider J, Garrison A, Geisbert J, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003;21:4071-80
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006;13:1267-77
   PubMed Web of Science ®Google Scholar
• Grant-Klein RJ, Van Deusen NM, Badger CV, et al. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Hum Vaccin Immunother 2012;8(11):1703-6
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Aviles J, Talbott KT, et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 2013;21:1432-44
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605-9
   PubMed Web of Science ®Google Scholar
• Aoki K, Barker C, Danthinne X, et al. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol Med 1999;5:224-31
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424:681-4
   PubMed Web of Science ®Google Scholar
• Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009;4:e5308
   PubMed Web of Science ®Google Scholar
• Richardson JS, Pillet S, Bello AJ, Kobinger GP. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 2013;87(7):3668-77
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010;28:950-7
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006;346:394-401
   PubMed Web of Science ®Google Scholar
• Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008;3:e3548
   PubMed Web of Science ®Google Scholar
• Richardson JS, Abou MC, Tran KN, et al. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis 2011;204(Suppl 3):S1032-42
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011;85:4222-33
   PubMed Web of Science ®Google Scholar
• Choi JH, Schafer SC, Zhang L. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm 2012;9:156-67
   PubMed Web of Science ®Google Scholar
• Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010;17:572-81
   PubMed Web of Science ®Google Scholar
• Roy S, Zhi Y, Kobinger GP, et al. Generation of an adenoviral vaccine vector based on simian adenovirus 21. J Gen Virol 2006;87:2477-85
   PubMed Web of Science ®Google Scholar
• Zahn R, Gillisen G, Roos A, et al. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One 2012;7:e44115
   PubMed Web of Science ®Google Scholar
• Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008;15:460-7
   PubMed Web of Science ®Google Scholar
• Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010;6:e1000904
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010;29:304-13
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011;17:1128-31
   PubMed Web of Science ®Google Scholar
• Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012;4:158ra46
   Web of Science ®Google Scholar
• Halfmann P, Kim JH, Ebihara H, et al. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci USA 2008;105:1129-33
   PubMed Web of Science ®Google Scholar
• Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis 2011;204(Suppl 3):S986-90
   PubMed Web of Science ®Google Scholar
• Halfmann P, Ebihara H, Marzi A, et al. Replication-deficient ebolavirus as a vaccine candidate. J Virol 2009;83:3810-15
   PubMed Web of Science ®Google Scholar
• Moss B. Poxviridae: the viruses and their replication. In: Knipe DM, Howley PM, editor. Fields Virology. Lippincott Williams & Wilkins, Philadelphia PA, USA; 2006. p. 2906-45
   Google Scholar
• Gilligan JK GJ, Jahrling PB, Anderson K. Assessment of protective immunity conferred by recombinant vaccinia virus to guinea pigs challenged with ebola virus. In: BD, Brown FDoherty P, Mekalanos J, Norrby E, editor. Vaccines. cold spring harbor. Lanoratory Press, Cold Spring Habor, NY, USA; 1997. p. 87-92
   Google Scholar
• Tsuda Y, Caposio P, Parkins CJ, et al. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 2011;5:e1275
   PubMed Web of Science ®Google Scholar
• Durbin AP, Skiadopoulos MH, McAuliffe JM, et al. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol 2000;74:6821-31
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Yang L, Zaki SR, et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006;80:2267-79
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007;81:6379-88
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Marzi A, Feldmann F, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009;383:348-61
   PubMed Web of Science ®Google Scholar
• Bukreyev AA, Dinapoli JM, Yang L, et al. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology 2010;399:290-8
   PubMed Web of Science ®Google Scholar
• DiNapoli JM, Yang L, Samal SK, et al. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010;29:17-25
   PubMed Web of Science ®Google Scholar
• Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Scie U S A, 1995;92:4477-81
   PubMed Web of Science ®Google Scholar
• Marzi A, Feldmann H, Geisbert TW, Falzarano D. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef 2011;S1
   Google Scholar
• Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 2012;6:e1567
   PubMed Web of Science ®Google Scholar
• Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-49
   PubMed Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004;78:5458-65
   PubMed Web of Science ®Google Scholar
• Jones SM, Stroher U, Fernando L, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007;196(Suppl 2):S404-12
   PubMedGoogle Scholar
• Marzi A, Ebihara H, Callison J, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 2011;204(Suppl 3):S1066-74
   PubMed Web of Science ®Google Scholar
• Tsuda Y, Safronetz D, Brown K, et al. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis 2011;204(Suppl 3):S1090-7
   PubMedGoogle Scholar
• Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11:786-90
   PubMed Web of Science ®Google Scholar
• Qiu X, Fernando L, Alimonti JB, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 2009;4:e5547
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008;26:6894-900
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 2009;83:7296-304
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013;110:1893-8
   PubMed Web of Science ®Google Scholar
• McGettigan JP, Pomerantz RJ, Siler CA, et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 2003;77:237-44
   PubMed Web of Science ®Google Scholar
• Blaney JE, Wirblich C, Papaneri AB, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol 2011;85:10605-16
   PubMed Web of Science ®Google Scholar
• Papaneri AB, Wirblich C, Cann JA, et al. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology 2012;434:18-26
   PubMedGoogle Scholar
• Papaneri AB, Wirblich C, Cooper K. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine 2012;30:6136-41
   PubMedGoogle Scholar
• Blaney JE, Marzi A, Willet M, et al. Antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 2013;9:e1003389
   PubMed Web of Science ®Google Scholar